Lipocine (NASDAQ:LPCN) Downgraded to “Sell” Rating by Wall Street Zen

Wall Street Zen lowered shares of Lipocine (NASDAQ:LPCN) from a hold rating to a sell rating in a research report report published on Saturday morning.

Other analysts have also issued reports about the stock. HC Wainwright reissued a “buy” rating and set a $15.00 price target (up from $7.00) on shares of Lipocine in a research report on Wednesday, January 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lipocine in a research report on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $15.00.

Lipocine Trading Down 8.8%

LPCN opened at $7.34 on Friday. The firm has a market cap of $40.74 million, a price-to-earnings ratio of -4.35 and a beta of 0.98. Lipocine has a 12 month low of $2.52 and a 12 month high of $12.37. The stock has a fifty day moving average price of $9.08 and a 200-day moving average price of $5.35.

Lipocine (NASDAQ:LPCN) last issued its quarterly earnings data on Monday, March 9th. The specialty pharmaceutical company reported ($0.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.26. Lipocine had a negative return on equity of 59.30% and a negative net margin of 487.00%.The firm had revenue of $1.15 million during the quarter, compared to analysts’ expectations of $0.12 million.

Institutional Investors Weigh In On Lipocine

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Citadel Advisors LLC acquired a new stake in Lipocine in the third quarter worth about $41,000. Geode Capital Management LLC increased its holdings in shares of Lipocine by 2.2% during the fourth quarter. Geode Capital Management LLC now owns 62,450 shares of the specialty pharmaceutical company’s stock valued at $502,000 after acquiring an additional 1,374 shares in the last quarter. Renaissance Technologies LLC increased its holdings in shares of Lipocine by 3.6% during the fourth quarter. Renaissance Technologies LLC now owns 37,397 shares of the specialty pharmaceutical company’s stock valued at $300,000 after acquiring an additional 1,300 shares in the last quarter. Jane Street Group LLC purchased a new position in shares of Lipocine in the 4th quarter valued at approximately $85,000. Finally, Persistent Asset Partners Ltd purchased a new position in shares of Lipocine in the 4th quarter valued at approximately $567,000. 9.11% of the stock is currently owned by hedge funds and other institutional investors.

Lipocine Company Profile

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.